arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

VolitionRX Limited

VNRX Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$0.17
▼ -0.5% Today
as of Oct 22, 16:53 ET
Last 30 days -45.16% Sep 14 → Oct 22
$0.16 $0.20 $0.24 $0.28 $0.32 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$0.17
High
$0.17
Low
$0.16
Volume
$2M
Avg Vol
$2M
Mkt Cap
$7M
P/E (TTM)
—
Beta
—
52w High
$9.60
52w Low
$0.16
Div Yield
—
Shares Out
$12M

Recent Press Releases & News last 60 days · 6 items

Sep 17 · 13:17 PR PR Newswire
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
Sep 17 · 12:17 PR PR Newswire
VolitionRx Participates in Launch of DETECSEPS Program in France
Sep 14 · 16:17 Zacks Small Cap Research
VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.
▸ Show all 6 press releases & news Free account →

VNRX earnings at a glance

The options market is pricing a move of about ±2042.7% after the report, a range of roughly -$3.30 to $3.64 from today's $0.17. Over its last 2 reports the stock rose the next day 0 times and fell 2, moving ±5.5% on average; after the most recent report on May 14, 2026 it moved -6.8%. That means options currently expect more movement than VNRX has typically delivered. VNRX beat the consensus EPS estimate in 0 of its last 4 reported quarters. Implied volatility is currently 173%. The share price of $0.17 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$0.16
$9.60
0% of range
Avg surprise (last 4)
-9.3%
Avg reaction (last 2)
-5.5%
0% positive
Latest IV / EM
17293%
EM ±2042.7% · $3 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.85$-0.65$-0.45$-0.24$-0.04 Actual $-0.10Actual $-0.08Actual $-0.07Actual $-0.06Est $-0.06Actual $-0.06Est $-0.05Actual $-0.04Est $-0.04Actual $-0.82Est $-0.70Actual $-0.85 MarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-7M$-5M$-3M$-1M$1M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.85 — — — — financials
Thu May 14, 2026Mar/2026 $-0.82 $-0.70 -17.1% -1,267% -6.8% earnings
Thu Nov 13, 2025Sep/2025 $-0.04 $-0.04 0.0% — — earnings
Thu Aug 14, 2025Jun/2025 $-0.06 $-0.05 -20.0% — — earnings
Thu May 15, 2025Mar/2025 $-0.06 $-0.06 0.0% — -4.3% earnings
Mon Sep 30, 2024Sep 2024 $-0.07 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.08 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.10 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$398,657$985,076—$627,277$406,688$246,385—$474,522
Cost of revenue————————
Gross profit————————
Operating income$-4M$-5M—$-5M$-6M$-6M—$-6M
Net income$-7M$-7M—$-5M$-6M$-5M—$-6M
EPS (diluted)$-0.85$-0.97—$-0.05$-1.22$-1.12—$-0.07

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$3M——$200,000$2M$3M——
Inventory————————
Total current assets$4M$5M$2M$1M$3M$3M$4M$7M
Total assets$8M$9M$7M$6M$9M$9M$9M$13M
Long-term debt$6M$6M$6M$6M$6M$6M$4M$4M
Total liabilities$42M$42M$42M$42M$42M$38M$36M$35M
Total equity$-32M$-33M$-34M$-35M$-33M$-29M$-25M$-23M

Implied volatility — last 90 days

436%9508%18581%27654%36727% Jun 08 — IV 1204% · EM ±159.0%Jun 09 — IV 2289% · EM ±286.8%Jun 10 — IV 2413% · EM ±285.0%Jun 19 — IV 744% · EM ±164.3%Jun 22 — IV 436% · EM ±91.1%Jun 23 — IV 792% · EM ±162.1%Jun 24 — IV 771% · EM ±154.4%Jun 25 — IV 1020% · EM ±199.8%Jun 26 — IV 1061% · EM ±203.1%Jun 29 — IV 447% · EM ±79.2%Jun 30 — IV 700% · EM ±120.6%Jul 01 — IV 1012% · EM ±169.1%Jul 02 — IV 778% · EM ±125.8%Jul 03 — IV 788% · EM ±123.2%Jul 06 — IV 1029% · EM ±142.6%Jul 07 — IV 1011% · EM ±133.5%Jul 08 — IV 1475% · EM ±184.8%Jul 09 — IV 2016% · EM ±238.1%Jul 10 — IV 3117% · EM ±344.4%Jul 13 — IV 2440% · EM ±203.8%Jul 14 — IV 2612% · EM ±189.0%Jul 15 — IV 4089% · EM ±241.5%Jul 16 — IV 9598% · EM ±400.9%Jul 20 — IV 1021% · EM ±241.2%Jul 21 — IV 1143% · EM ±265.8%Jul 22 — IV 2249% · EM ±514.4%Jul 23 — IV 1267% · EM ±285.0%Jul 24 — IV 1425% · EM ±315.0%Jul 27 — IV 1627% · EM ±339.8%Jul 28 — IV 1923% · EM ±393.5%Jul 29 — IV 3231% · EM ±647.2%Jul 30 — IV 3247% · EM ±636.1%Jul 31 — IV 2802% · EM ±536.2%Aug 03 — IV 3598% · EM ±637.5%Aug 04 — IV 1922% · EM ±331.0%Aug 05 — IV 3907% · EM ±652.7%Aug 06 — IV 5176% · EM ±837.2%Aug 07 — IV 3384% · EM ±528.8%Aug 10 — IV 4800% · EM ±664.9%Aug 11 — IV 5456% · EM ±720.6%Aug 12 — IV 7342% · EM ±919.8%Aug 14 — IV 4600% · EM ±508.3%Aug 18 — IV 12830% · EM ±928.1%Aug 19 — IV 14396% · EM ±850.2%Aug 20 — IV 21145% · EM ±883.1%Aug 24 — IV 5267% · EM ±1099.7%Aug 25 — IV 5274% · EM ±1079.0%Aug 26 — IV 5657% · EM ±1133.0%Aug 27 — IV 3946% · EM ±772.9%Aug 28 — IV 5349% · EM ±1023.6%Aug 31 — IV 5819% · EM ±1031.1%Sep 01 — IV 6409% · EM ±1103.6%Sep 02 — IV 6774% · EM ±1131.6%Sep 03 — IV 7868% · EM ±1272.7%Sep 04 — IV 8128% · EM ±1270.1%Sep 07 — IV 8983% · EM ±1244.3%Sep 08 — IV 9927% · EM ±1311.0%Sep 09 — IV 10152% · EM ±1271.9%Sep 10 — IV 10660% · EM ±1259.2%Sep 11 — IV 12691% · EM ±1402.3%Sep 14 — IV 16326% · EM ±1363.6%Sep 15 — IV 22018% · EM ±1592.7%Sep 16 — IV 24268% · EM ±1433.3%Sep 17 — IV 36727% · EM ±1533.8%Sep 21 — IV 7785% · EM ±1625.7%Sep 22 — IV 8642% · EM ±1768.1%Sep 23 — IV 9360% · EM ±1874.7%Sep 24 — IV 9729% · EM ±1905.7%Sep 25 — IV 9474% · EM ±1813.2%Sep 28 — IV 10362% · EM ±1836.0%Sep 29 — IV 10322% · EM ±1777.3%Sep 30 — IV 10744% · EM ±1794.9%Oct 01 — IV 11965% · EM ±1935.3%Oct 02 — IV 12527% · EM ±1957.4%Oct 06 — IV 14661% · EM ±1936.2%Oct 07 — IV 16952% · EM ±2123.9%Oct 08 — IV 17293% · EM ±2042.7%

Sector peers

CDIO
Cardio Diagnostics Holdings Inc.
$6M $1.71-0.9%
VRAX
Virax Biolabs Group Limited
$3M $1.24-9.8%
QCLS
Q/C Technologies, Inc.
$19M $0.53+6.0%
ICCC
ImmuCell Corporation
$87M $10.44-0.1%
IMDX
Insight Molecular Diagnostics Inc.
$114M $2.84-6.3%
MYGN
Myriad Genetics, Inc.
$409M $5.76+4.0%

VNRX earnings FAQ

What is VNRX's expected move for earnings?

Options currently price a move of about ±2042.7%, or $3.47 per share either way from $0.17.

How does VNRX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±5.5%, up 0 times and down 2 times.

What is VNRX's implied volatility?

VNRX's at-the-money implied volatility is about 173% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in